Gatifloxacin versus ceftriaxone for uncomplicated enteric fever in Nepal: an open-label, two-centre, randomized controlled trial

Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would b...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Arjyal, Amit, Basnyat, Buddha, Nhan, Ho Thi, Koirala, Samir, Giri, Abhishek, Joshi, Niva, Shakya, Mila, Pathak, Kamal Raj, Mahat, Saruna Pathak, Prajapati, Shanti Pradhan, Adhikari, Nabin, Thapa, Rajkumar, Merson, Laura, Gajurel, Damodar, Lamsal, Kamal, Lamsal, Dinesh, Yadav, Bharat Kumar, Shah, Ganesh, Shrestha, Poojan, Dongol, Sabina, Karkey, Abhilasha, Thompson, Corinne N, Thieu, Nga Tran Vu, Thanh, Duy Pham, Baker, Stephen, Thwaites, Guy E, Wolbers, Marcel, Dolecek, Christiane
स्वरूप: Technical Report
भाषा:en_US
प्रकाशित: Lancet Infect Dis 2016 2016
विषय:
ऑनलाइन पहुंच:http://103.69.126.140:8080/handle/123456789/818
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
विवरण
सारांश:Background Because treatment with third-generation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric fever, whereas the fluoroquinolone gatifloxacin is associated with rapid fever clearance and low relapse burden, we postulated that gatifloxacin would be superior to the cephalosporin ceftriaxone in treating enteric fever.